Journal profile · ONCOLOGY
Current Oncology Reports
ISSN 1523-3790 · eISSN 1534-6269 · Springer US · UNITED STATES · 12 issues per year · Founded 1999
Current Oncology Reports: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.2; hybrid open access; APC about USD 5,090; median 71 days to acceptance (104 articles, last 24 months); 115 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Oncology Reports is published by Springer US and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lymphoma Diagnosis and Treatment and CAR-T cell therapy research, together about 18.4% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer.We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Maurie MarkmanPublisher website
Editorial board by country: none in mainland China; most named United States 22, United Kingdom 4, Hong Kong, China 2, Netherlands 2, Japan 1 (40 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine6.6%
- Lymphoma Diagnosis and TreatmentMedicine6.3%
- CAR-T cell therapy researchMedicine5.5%
- Glioma Diagnosis and TreatmentMedicine5.4%
- Lung Cancer Treatments and MutationsMedicine5%
- Ovarian cancer diagnosis and treatmentMedicine4.5%
- Lung Cancer Research StudiesMedicine4.5%
- Head and Neck Cancer StudiesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.2LetPub ·
- Impact factor (publisher) 2025
- 5.2Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.6Publisher website ·
- CiteScore 2026-06
- 9.8LetPub ·
- SJR 2026-06
- 1.6LetPub ·
- SNIP 2026-06
- 1.63LetPub ·
- h-index
- 52LetPub ·
- h-index
- 103OpenAlex ·
- i10-index
- 1,536OpenAlex ·
- 2-year mean citedness
- 6.56OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 34.32%LetPub ·
Volume
- Articles per year
- 111LetPub ·
- Downloads per year (publisher) 2025
- 891,100Publisher website ·
Articles by year OpenAlex count · 2,586 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 98 | 47 | 54 |
| 2025 | 115 | 56 | 684 |
| 2024 | 139 | 55 | 1,572 |
| 2023 | 129 | 58 | 2,362 |
| 2022 | 189 | 74 | 4,410 |
| 2021 | 143 | 58 | 5,084 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
71 daysMedian, submission to acceptance · P25–P75 41 days – 112 days
- Acceptance to online
- median 21 days (104 articles)
- Submission to online
- median 114 days
- Sample
- 104 articles with submission and acceptance dates (249 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Submission to first decision
- 4 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,090 / EUR 3,990 / GBP 3,190 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted4
- commentaryReviews and Invited Commentaries Back to topLength not stated
- invited commentariesTypes of papers Reviews and Invited CommentariesLength not stated
- reviewReviews and Invited Commentaries Back to topLength not stated
- reviewsTypes of papers Reviews and Invited CommentariesLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Plagiarism, Trial registration / reporting guidelines
- AI use Generative AI Images
LLM use policy Model summary
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
Data transparency policy Model summary
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
Committee on Publication Ethics (COPE) member Model summary
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Current Oncology Reports, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review
Reviewer suggestion allowed Model summary
Authors are welcome to suggest suitable reviewers and/or request the exclusion of certain individuals when they submit their manuscripts.
Source ↗Publisher website ·- Plagiarism
Software screening for plagiarism Model summary
Important note: the journal may use software to screen for plagiarism.
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- 12 issues per year
- Founded
- 1999
- ISSN
- 1523-3790
- Electronic ISSN
- 1534-6269
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Current Oncology Reports
What CAS zone is Current Oncology Reports in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Oncology Reports is in Zone 2 of Medicine, and in Zone 2 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Oncology Reports?
The latest impact factor listed by LetPub is 5.2; CiteScore 9.8, h-index 103.
How long does peer review take at Current Oncology Reports?
Based on the dates recorded on 104 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 71 days (interquartile range 41–112 days); authors report an average review time of 6–12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Current Oncology Reports?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Current Oncology Reports based?
Of the 40 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (22), United Kingdom (4) and Hong Kong, China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Current Oncology Reports?
According to LetPub and DOAJ records, Current Oncology Reports is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Current Oncology Reports open access, and what is the APC?
Current Oncology Reports is a hybrid journal. For open-access publication: APC about USD 5,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .